4D Molecular Therapeutics
Industry
- Pharmaceuticals
- Drug Delivery
- Macromolecule
- Drug Delivery
- Biotechnology
- Large Molecule
- Gene Therapy, Cell Therapy
Other Names/Subsidiaries
- 4DMT
Latest on 4D Molecular Therapeutics
4D Molecular Therapeutics (4DMT) has accelerated its Phase III program for 4D-150 for wet age-related macular degeneration (AMD), with top-line data from the North American 4FRONT-1 trial now expected
“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru
Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b